Study of Bortezomib in Combination With Cyclophosphamide and Rituximab

Phase 2 Completed 22 enrolled M.D. Anderson Cancer Center Millennium Pharmaceuticals, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if bortezomib when given in combination with cyclophosphamide and rituximab can help to control mantle cell lymphoma. The safety of this drug combination will also continue to be studied.

Timeline

Start: 2009-08
Primary completion: 2014-03
Completion: 2014-03

Publications

Lee HJ, Romaguera JE, Feng L, Desai AP, Zhang L, Fanale M, Samaniego F, Hagemeister FB, Fayad LE, Rodriguez MA, Medeiros JL, Hartig K, Nomie K, Ahmed M, Badillo M, Ye H, Oki Y, Lin P, Nastoupil L, Westin J, Wang M. Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma. Oncologist. 2017 May;22(5):549-553. doi: 10.1634/theoncologist.2016-0328. Epub 2017 Apr 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bortezomib	Small molecule	1.3 mg/m2	Intravenous
Subject	Cyclophosphamide	Other / unclassified	300 mg/m2	Intravenous
Subject	Rituximab	Monoclonal antibody	375 mg/m2	Intravenous
Background	2-MERCAPTOETHANESULFONIC ACID	Small molecule	600 mg/m2	Intravenous
Background	G-CSF	Unknown	5 ug/kg	Subcutaneous

Study of Bortezomib in Combination With Cyclophosphamide and Rituximab

Summary

Timeline

Publications

Drugs

Indications